151 related articles for article (PubMed ID: 37268672)
1. Simple new clinical score to predict hepatocellular carcinoma after sustained viral response with direct-acting antivirals.
Watanabe T; Tokumoto Y; Joko K; Michitaka K; Horiike N; Tanaka Y; Hiraoka A; Tada F; Ochi H; Kisaka Y; Nakanishi S; Yagi S; Yamauchi K; Higashino M; Hirooka K; Morita M; Okazaki Y; Yukimoto A; Hirooka M; Abe M; Hiasa Y
Sci Rep; 2023 Jun; 13(1):8992. PubMed ID: 37268672
[TBL] [Abstract][Full Text] [Related]
2. Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication.
Lu MY; Yeh ML; Huang CI; Wang SC; Tsai YS; Tsai PC; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Chen SC; Huang CF; Huang JF; Dai CY; Chuang WL; Yu ML
World J Gastroenterol; 2022 Jan; 28(1):140-153. PubMed ID: 35125824
[TBL] [Abstract][Full Text] [Related]
3. Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C.
Chun HS; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Lee CH; Lee YB; Cho EJ; Yu SJ; Kim YJ; Yoon JH; Lee JH; Kim SU
Eur J Gastroenterol Hepatol; 2020 Mar; 32(3):378-385. PubMed ID: 32011388
[TBL] [Abstract][Full Text] [Related]
4. Liver stiffness-based score at sustained virologic response predicts liver-related complications after eradication of hepatitis C virus.
Kuo YH; Kee KM; Hung CH; Lu SN; Hu TH; Chen CH; Wang JH
Kaohsiung J Med Sci; 2022 Mar; 38(3):268-276. PubMed ID: 34687140
[TBL] [Abstract][Full Text] [Related]
5. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
Kuwano A; Yada M; Nagasawa S; Tanaka K; Morita Y; Masumoto A; Motomura K
J Viral Hepat; 2022 Jan; 29(1):35-42. PubMed ID: 34661320
[TBL] [Abstract][Full Text] [Related]
6. Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response.
Azzi J; Dorival C; Cagnot C; Fontaine H; Lusivika-Nzinga C; Leroy V; De Ledinghen V; Tran A; Zoulim F; Alric L; Gournay J; Bronowicki JP; Decaens T; Riachi G; Mikhail N; Soliman R; Shiha G; Pol S; Carrat F; Ganne-Carrié N;
Clin Res Hepatol Gastroenterol; 2022; 46(6):101923. PubMed ID: 35405354
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
[TBL] [Abstract][Full Text] [Related]
8. Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals.
Tahata Y; Sakamori R; Yamada R; Kodama T; Hikita H; Hagiwara H; Imai Y; Hiramatsu N; Tamura S; Yamamoto K; Oshita M; Ohkawa K; Hijioka T; Fukui H; Ito T; Doi Y; Yamada Y; Yakushijin T; Yoshida Y; Tatsumi T; Takehara T;
Aliment Pharmacol Ther; 2021 Nov; 54(10):1340-1349. PubMed ID: 34618934
[TBL] [Abstract][Full Text] [Related]
9. Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct-acting antivirals.
Sugiura A; Joshita S; Umemura T; Yamazaki T; Fujimori N; Kimura T; Matsumoto A; Igarashi K; Usami Y; Wada S; Mori H; Shibata S; Yoshizawa K; Morita S; Furuta K; Kamijo A; Iijima A; Kako S; Maruyama A; Kobayashi M; Komatsu M; Matsumura M; Miyabayashi C; Ichijo T; Takeuchi A; Koike Y; Gibo Y; Tsukadaira T; Inada H; Kiyosawa K; Tanaka E
J Viral Hepat; 2018 Dec; 25(12):1462-1471. PubMed ID: 30044517
[TBL] [Abstract][Full Text] [Related]
10. Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus.
Tamaki N; Kurosaki M; Yasui Y; Mori N; Tsuji K; Hasebe C; Joko K; Akahane T; Furuta K; Kobashi H; Kimura H; Yagisawa H; Marusawa H; Kondo M; Kojima Y; Yoshida H; Uchida Y; Loomba R; Izumi N
Clin Infect Dis; 2021 Nov; 73(9):e3349-e3354. PubMed ID: 33544129
[TBL] [Abstract][Full Text] [Related]
11. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy.
Nagaoki Y; Imamura M; Nishida Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Fujino H; Nakahara T; Kawaoka T; Tsuge M; Hiramatsu A; Kawakami Y; Miki D; Hiyama Y; Ochi H; Chayama K; Aikata H
J Med Virol; 2019 Apr; 91(4):650-658. PubMed ID: 30381831
[TBL] [Abstract][Full Text] [Related]
12. Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C.
Ahn YH; Lee H; Kim DY; Lee HW; Yu SJ; Cho YY; Jang JW; Jang BK; Kim CW; Kim HY; Park H; Cho HJ; Park B; Kim SS; Cheong JY
Gut Liver; 2021 May; 15(3):410-419. PubMed ID: 32893194
[TBL] [Abstract][Full Text] [Related]
13. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
Singal AG; Lim JK; Kanwal F
Gastroenterology; 2019 Jun; 156(8):2149-2157. PubMed ID: 30878469
[TBL] [Abstract][Full Text] [Related]
14. Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals.
Tamaki N; Higuchi M; Kurosaki M; Kirino S; Osawa L; Watakabe K; Wang W; Okada M; Shimizu T; Takaura K; Takada H; Kaneko S; Yasui Y; Tsuchiya K; Nakanishi H; Itakura J; Takahashi Y; Enomoto N; Izumi N
J Viral Hepat; 2019 Jul; 26(7):893-899. PubMed ID: 30974045
[TBL] [Abstract][Full Text] [Related]
15. Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus.
Kumada T; Toyoda H; Yasuda S; Ito T; Tsuji K; Fujioka S; Hiraoka A; Kariyama K; Nouso K; Ishikawa T; Tamai T; Tada T; Tanaka J
J Viral Hepat; 2022 Oct; 29(10):919-929. PubMed ID: 35790055
[TBL] [Abstract][Full Text] [Related]
16. Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease.
Ogata F; Kobayashi M; Akuta N; Osawa M; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Suzuki F; Arase Y; Ikeda K; Kumada H
Oncology; 2017; 93(2):92-98. PubMed ID: 28448999
[TBL] [Abstract][Full Text] [Related]
17. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N
Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals.
Ravaioli F; Conti F; Brillanti S; Andreone P; Mazzella G; Buonfiglioli F; Serio I; Verrucchi G; Bacchi Reggiani ML; Colli A; Marasco G; Colecchia A; Festi D
Dig Liver Dis; 2018 Jun; 50(6):573-579. PubMed ID: 29567413
[TBL] [Abstract][Full Text] [Related]
19. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
Tsai PC; Kuo HT; Hung CH; Tseng KC; Lai HC; Peng CY; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Tai CM; Lin CW; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Yeh ML; Huang CF; Hsieh MH; Huang JF; Dai CY; Chung WL; Chen CY; Yu ML;
J Hepatol; 2023 Feb; 78(2):281-292. PubMed ID: 36208843
[TBL] [Abstract][Full Text] [Related]
20. Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study.
Rinaldi L; Perrella A; Guarino M; De Luca M; Piai G; Coppola N; Pafundi PC; Ciardiello F; Fasano M; Martinelli E; Valente G; Nevola R; Monari C; Miglioresi L; Guerrera B; Berretta M; Sasso FC; Morisco F; Izzi A; Adinolfi LE
J Transl Med; 2019 Aug; 17(1):292. PubMed ID: 31462268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
